A Phase 2 interventional study of Belimumab 10 mg/kg and Placebo in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Completed at 32 sites in 10 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 17th largest by enrollment, is one of 5 that started in 2012, is one of 8 in phase 2, and was the 17th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 5 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 93 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 18th largest by enrollment of the 36 interventional ones that give a count, is one of 8 that started in 2012, is one of 7 in phase 2, and was the 22nd registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
This is a multi-center study to evaluate the safety, pharmacokinetics, and efficacy of belimumab intravenous (IV) in pediatric patients 5 to 17 years of age with active systemic lupus erythematosus
This is a multi-center study to evaluate the safety, pharmacokinetics, and efficacy of belimumab intravenous (IV) in pediatric patients 5 to 17 years of age with active systemic lupus erythematosus (SELENA SLEDAI score ≥ 6). The study will consist of three phases: a 52-week randomized, placebo-controlled, double-blind phase; a long term open label continuation phase; and a long term safety follow up phase. The long term open label continuation and safety follow up periods will continue for at least 5 years and possibly up to 10 years from a subject's initial treatment with belimumab. Enrolment will be staggered by age cohorts to allow safety and PK interim analyses. Subjects will be randomized to belimumab 10mg/kg or placebo IV monthly dosing while continuing to receive background standard therapy throughout the study. An independent data monitoring committee (IDMC) will monitor the study as it progresses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received saline infusion (placebo) intravenously monthly for 48 weeks on a background of standard of care.
Other: Placebo
Participants received 10 milligrams per kilograms (mg/kg) reconstituted solution intravenously monthly for 48 weeks on a background of standard of care.
Drug: Belimumab 10 mg/kg
Participants who entered Part B after completing 48 weeks of belimumab or placebo on a background of standard of care and the Week 52 assessments in Part A, received 10 mg/kg belimumab intravenously monthly up to 10 years from the first administration of belimumab.
Drug: Belimumab 10 mg/kg
Participants who entered Part C after discontinuing study intervention in Part A or Part B were included in this arm.
Drug page: Belimumab
Belimumab was administered.
Placebo was administered
Also known as: Normal Saline
Percentage of Participants With SLE Responder Index (SRI) Response at Week 52
SRI response is defined as \>=4 point reduction, from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score, no worsening (increase of \<0.30 points from Baseline) in physician's global assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SELENA SLEDAI score (\<=12 vs. \>=13). Percentage of participants with SRI response at Week 52 of Part A were reported. Intent-to-Treat Population comprised of all participants who were randomized and treated with at least one dose of study agent in Part A. One participant had missing data at Baseline and therefore, could not be included in the analysis.
Time frame: Week 52
Percentage of Participants Meeting Pediatric Rheumatology International Trials Organization (PRINTO)/ American College of Rheumatology (ACR) Juvenile SLE Response Evaluation Criteria for Improvement in Juvenile SLE at Week 52 Using Definition 1 and 2
Percentage of participants meeting PRINTO/ACR Juvenile SLE Response Evaluation criteria for improvement in juvenile SLE using two different PRINTO/ACR Juvenile SLE Response Evaluation definitions of improvement that is Definition 1: At least 50% improvement in any 2 of 5 endpoints below and no more than 1 of the remaining worsening by more than 30% and Definition 2: At least 30% improvement in 3 of 5 endpoints below and no more than 1 of the remaining worsening more than 30%. Endpoints were: 1. Percent change in Parent's Global Assessment (ParentGA) at Week 52, 2. Percent change in PGA at Week 52, 3. Percent change in SELENA SLEDAI score at Week 52, 4. Percent change in Pediatric Quality of Life Inventory (PedsQL) physical functioning domain at Week 52, 5. Percent change in 24 hour proteinuria at Week 52 (gram/24hour equivalent by spot urine protein to creatinine ratio).
Time frame: Week 52
Percent Change From Baseline in ParentGA at Week 52
ParentGA assesses the participant's overall well-being at the moment rated on a 21-numbered circle visual analog scale (VAS; 0 - very well, 10 - very poorly). Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. Last Observation Carried Forward (LOCF) was used. Eight participants had a score of zero at Baseline and therefore, could not be included in the analysis.
Time frame: Baseline (Day 0) and Week 52
Percent Change From Baseline in PGA at Week 52
The PGA is a 10 centimeter (cm) visual analogue scale (VAS), anchored at 0 (none) and 3 (severe), designed for the physician to indicate the participant's overall disease activity at a particular visit as part of the validated SELENA SLEDAI index. Primary investigator or a subinvestigator scored the PGA for the participant, and same person evaluated the participant each time. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. LOCF was used.
Time frame: Baseline (Day 0) and Week 52
Percent Change From Baseline in SELENA SLEDAI at Week 52
The SELENA SLEDAI score is a weighted index for assessing SLE disease activity in which signs and symptoms, laboratory tests and physician's assessment for each of 9 organ system were given a weighted score and summed if present at the time of the visit or in the preceding 10 days. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. A decrease of 4 points or more equates to a clinically meaningful improvement. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. One participant had missing data at Baseline and therefore, could not be included in the analysis.
Time frame: Baseline (Day 0) and Week 52
Percent Change From Baseline in PedsQL Physical Functioning Domain Score at Week 52
The PedsQL is a generic quality of life scale validated for the pediatric population which consists of 23 items, encompassing 4 health domains: Physical Functioning (8 items), Emotional Functioning (5 items), Social Functioning (5 items), and School Functioning (5 items). From the raw scores of the 23 items, a total summary score and individual domain scores can be calculated. The total and domain scores are each transformed on a 0 to 100 score with higher scores indicating higher quality of life. For Physical Functioning Domain scale, score was from 0 to 100 where, 0 indicates lower quality of life and 100 indicates greater quality of life. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline Value X 100. LOCF was used.
Time frame: Baseline (Day 0) and Week 52
Percent Change From Baseline in Proteinuria at Week 52
Percent change from Baseline in proteinuria was calculated. The percent change from baseline to Week 52 in 24 hour proteinuria was analyzed using summary statistics and 95% confidence intervals, without any adjustment for covariates. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline Value X 100. LOCF was used.
Time frame: Baseline (Day 0) and Week 52
Percentage of Participants With a Sustained SRI Response
Sustained SRI response was defined as having a response on the primary efficacy endpoint at Weeks 44, 48, and 52. Data for percentage of participants with a sustained SRI response was presented. Drop Outs and Treatment Failures were considered Non-Responders. Only those participants with data available at specific time point were analyzed.
Time frame: Up to 52 weeks
Percentage of Participants With a Sustained ParentGA Response
Sustained ParentGA response was defined as having \>0.7 improvement at Weeks 44, 48, and 52 compared at Baseline. Data for percentage of participants with a sustained ParentGA response was presented. Thirteen participants had a score of \<=0.7 at Baseline and therefore, could not be included in the analysis.
Time frame: Up to 52 weeks
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with AEs and SAEs have been reported.
Time frame: Up to 60 weeks
Maximum Concentration at Steady State (Cmax, ss) and Minimum Concentration at Steady State (Cmin, ss)
The pharmacokinetic (PK) population comprised all participants included in the As- Treated population for whom at least one post belimumab treatment PK sample was obtained and analyzed. The PK model was fitted to the observed serum concentration-time data. The maximum (Cmax) and minimum (Cmin) concentrations reported in this table are model derived values at ss, assuming a 10 mg/kg dose administered once every 28 days.
Time frame: 28-days dosing interval at steady state
Area Under Curve of Belimumab at Steady State (AUC, ss)
The PK model was fitted to the observed serum concentration-time data. The AUC values reported in this table are model derived values at ss, assuming a 10 mg/kg dose administered once every 28 days.
Time frame: 28-days dosing interval at steady state
The study consisted of three parts (Parts A, B, and C). Part A was a parallel-group study where participants could receive either belimumab or placebo. Participants who completed 48 weeks of treatment and Week 52 assessments in Part A could continue to the open label extension phase (Part B) to receive belimumab. Participants who discontinued study intervention in Part A or Part B could enter the long-term safety follow-up phase (Part C).
| Milestone | Part A: Placebo | Part A: Belimumab 10 mg/kg | Part B: Open-Label Belimumab | Part C: Safety Follow-up Phase |
|---|---|---|---|---|
| Started | 40 | 53 | 0 | 0 |
| Completed | 31 | 45 | 0 | 0 |
| Not completed | 9 | 8 | 0 | 0 |
| Withdrew: Adverse event | 5 | 3 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 3 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 | 0 |
| Milestone | Part A: Placebo | Part A: Belimumab 10 mg/kg | Part B: Open-Label Belimumab | Part C: Safety Follow-up Phase |
|---|---|---|---|---|
| Started | 0 | 0 | 75 | 0 |
| Completed | 0 | 0 | 19 | 0 |
| Not completed | 0 | 0 | 56 | 0 |
| Withdrew: Physician decision | 0 | 0 | 14 | 0 |
| Withdrew: Adverse event | 0 | 0 | 10 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 10 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 10 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Withdrew: Long-term follow-up concluded early per pre-defined protocol criteria | 0 | 0 | 9 | 0 |
| Milestone | Part A: Placebo | Part A: Belimumab 10 mg/kg | Part B: Open-Label Belimumab | Part C: Safety Follow-up Phase |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 42 |
| Safety population | 0 | 0 | 0 | 38 |
| Completed | 0 | 0 | 0 | 12 |
| Not completed | 0 | 0 | 0 | 30 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 16 |
| Withdrew: Physician decision | 0 | 0 | 0 | 9 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 |
SRI response is defined as \>=4 point reduction, from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score, no worsening (increase of \<0.30 points from Baseline) in physician's global assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SELENA SLEDAI score (\<=12 vs. \>=13). Percentage of participants with SRI response at Week 52 of Part A were reported. Intent-to-Treat Population comprised of all participants who were randomized and treated with at least one dose of study agent in Part A. One participant had missing data at Baseline and therefore, could not be included in the analysis.
| Percentage of participants | Part A: Placebo | Part A: Belimumab 10 mg/kg |
|---|---|---|
| Percentage of Participants With SLE Responder Index (SRI) Response at Week 52 | 43.6 | 52.8 |
Percentage of participants meeting PRINTO/ACR Juvenile SLE Response Evaluation criteria for improvement in juvenile SLE using two different PRINTO/ACR Juvenile SLE Response Evaluation definitions of improvement that is Definition 1: At least 50% improvement in any 2 of 5 endpoints below and no more than 1 of the remaining worsening by more than 30% and Definition 2: At least 30% improvement in 3 of 5 endpoints below and no more than 1 of the remaining worsening more than 30%. Endpoints were: 1. Percent change in Parent's Global Assessment (ParentGA) at Week 52, 2. Percent change in PGA at Week 52, 3. Percent change in SELENA SLEDAI score at Week 52, 4. Percent change in Pediatric Quality of Life Inventory (PedsQL) physical functioning domain at Week 52, 5. Percent change in 24 hour proteinuria at Week 52 (gram/24hour equivalent by spot urine protein to creatinine ratio).
| Percentage of participants | Part A: Placebo | Part A: Belimumab 10 mg/kg |
|---|---|---|
| Definition 1 | 35.0 | 60.4 |
| Definition 2 | 27.5 | 52.8 |
ParentGA assesses the participant's overall well-being at the moment rated on a 21-numbered circle visual analog scale (VAS; 0 - very well, 10 - very poorly). Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. Last Observation Carried Forward (LOCF) was used. Eight participants had a score of zero at Baseline and therefore, could not be included in the analysis.
| Percent change | Part A: Placebo | Part A: Belimumab 10 mg/kg |
|---|---|---|
| Percent Change From Baseline in ParentGA at Week 52 | -23.61 (-95.0 to 600.0) | -53.85 (-100.0 to 900.0) |
The PGA is a 10 centimeter (cm) visual analogue scale (VAS), anchored at 0 (none) and 3 (severe), designed for the physician to indicate the participant's overall disease activity at a particular visit as part of the validated SELENA SLEDAI index. Primary investigator or a subinvestigator scored the PGA for the participant, and same person evaluated the participant each time. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. LOCF was used.
| Percent change | Part A: Placebo | Part A: Belimumab 10 mg/kg |
|---|---|---|
| Percent Change From Baseline in PGA at Week 52 | -48.802 ± 42.0423 | -56.525 ± 43.7939 |
The SELENA SLEDAI score is a weighted index for assessing SLE disease activity in which signs and symptoms, laboratory tests and physician's assessment for each of 9 organ system were given a weighted score and summed if present at the time of the visit or in the preceding 10 days. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. A decrease of 4 points or more equates to a clinically meaningful improvement. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline value X 100. One participant had missing data at Baseline and therefore, could not be included in the analysis.
| Percent change | Part A: Placebo | Part A: Belimumab 10 mg/kg |
|---|---|---|
| Percent Change From Baseline in SELENA SLEDAI at Week 52 | -38.0 ± 39.50 | -43.3 ± 43.73 |
The PedsQL is a generic quality of life scale validated for the pediatric population which consists of 23 items, encompassing 4 health domains: Physical Functioning (8 items), Emotional Functioning (5 items), Social Functioning (5 items), and School Functioning (5 items). From the raw scores of the 23 items, a total summary score and individual domain scores can be calculated. The total and domain scores are each transformed on a 0 to 100 score with higher scores indicating higher quality of life. For Physical Functioning Domain scale, score was from 0 to 100 where, 0 indicates lower quality of life and 100 indicates greater quality of life. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline Value X 100. LOCF was used.
| Percent change | Part A: Placebo | Part A: Belimumab 10 mg/kg |
|---|---|---|
| Percent Change From Baseline in PedsQL Physical Functioning Domain Score at Week 52 | 12.5 (-53 to 575) | 10.5 (-100 to 280) |
Percent change from Baseline in proteinuria was calculated. The percent change from baseline to Week 52 in 24 hour proteinuria was analyzed using summary statistics and 95% confidence intervals, without any adjustment for covariates. Baseline was defined as measurements at Day 0. Percent change from Baseline was calculated by subtracting the Baseline value from value at Week 52 divided by the Baseline Value X 100. LOCF was used.
| Percent change | Part A: Placebo | Part A: Belimumab 10 mg/kg |
|---|---|---|
| Percent Change From Baseline in Proteinuria at Week 52 | 7.0920 (-90.568 to 570.149) | -2.1277 (-85.073 to 1681.884) |
Sustained SRI response was defined as having a response on the primary efficacy endpoint at Weeks 44, 48, and 52. Data for percentage of participants with a sustained SRI response was presented. Drop Outs and Treatment Failures were considered Non-Responders. Only those participants with data available at specific time point were analyzed.
| Percentage of participants | Part A: Placebo | Part A: Belimumab 10 mg/kg |
|---|---|---|
| Percentage of Participants With a Sustained SRI Response | 41.0 | 43.4 |
Sustained ParentGA response was defined as having \>0.7 improvement at Weeks 44, 48, and 52 compared at Baseline. Data for percentage of participants with a sustained ParentGA response was presented. Thirteen participants had a score of \<=0.7 at Baseline and therefore, could not be included in the analysis.
| Percentage of participants | Part A: Placebo | Part A: Belimumab 10 mg/kg |
|---|---|---|
| Percentage of Participants With a Sustained ParentGA Response | 33.3 | 59.1 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with AEs and SAEs have been reported.
| Participants | Part A: Placebo | Part A: Belimumab 10 mg/kg |
|---|---|---|
| AEs | 33 | 42 |
| SAEs | 14 | 9 |
The pharmacokinetic (PK) population comprised all participants included in the As- Treated population for whom at least one post belimumab treatment PK sample was obtained and analyzed. The PK model was fitted to the observed serum concentration-time data. The maximum (Cmax) and minimum (Cmin) concentrations reported in this table are model derived values at ss, assuming a 10 mg/kg dose administered once every 28 days.
| Micrograms per milliliter | Part A: Belimumab 10 mg/kg |
|---|---|
| Cmax, ss | 315 ± 31.2 |
| Cmin, ss | 50 ± 68.3 |
The PK model was fitted to the observed serum concentration-time data. The AUC values reported in this table are model derived values at ss, assuming a 10 mg/kg dose administered once every 28 days.
| Days*micrograms per milliliter | Part A: Belimumab 10 mg/kg |
|---|---|
| Area Under Curve of Belimumab at Steady State (AUC, ss) | 3012 ± 43.2 |
Collected over Part A: From start of study intervention (Day 0) up to Week 60. Part B: From first dose of belimumab (Part A Day 0 for participants randomized to belimumab in Part A; Part A Week 52 for participants randomized to placebo in Part A) up to approximately 10.3 years. Part C: From Part C Day 1 (exit visit from Part A or B, or 28 days after last belimumab infusion in Part B) up to 12 weeks for non-SAEs and up to 10 years for SAEs.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Placebo | 1/40 (2.5%) | 14/40 (35%) | 27/40 (67.5%) |
| Part A: Belimumab 10 mg/kg | 0/53 (0%) | 9/53 (17%) | 36/53 (67.9%) |
| Part B: Open-Label Belimumab | 1/75 (1.3%) | 30/75 (40%) | 71/75 (94.7%) |
| Part C: Safety Follow-up Phase | 2/38 (5.3%) | 13/38 (34.2%) | 3/38 (7.9%) |
| Event | Part A: Placebo | Part A: Belimumab 10 mg/kg | Part B: Open-Label Belimumab | Part C: Safety Follow-up Phase |
|---|---|---|---|---|
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 0/40 | 1/53 | 5/75 | 3/38 |
| AppendicitisInfections and infestations | 0/40 | 0/53 | 1/75 | 2/38 |
| HeadacheNervous system disorders | 2/40 | 0/53 | 1/75 | 0/38 |
| Lupus nephritisRenal and urinary disorders | 2/40 | 2/53 | 2/75 | 1/38 |
| CellulitisInfections and infestations | 0/40 | 0/53 | 3/75 | 1/38 |
| GastroenteritisInfections and infestations | 0/40 | 1/53 | 3/75 | 1/38 |
| Acute kidney injuryRenal and urinary disorders | 0/40 | 0/53 | 2/75 | 0/38 |
| Autoimmune haemolytic anaemiaBlood and lymphatic system disorders | 0/40 | 0/53 | 0/75 | 1/38 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/40 | 0/53 | 0/75 | 1/38 |
| Cardiac failureCardiac disorders | 0/40 | 0/53 | 0/75 | 1/38 |
| Event | Part A: Placebo | Part A: Belimumab 10 mg/kg | Part B: Open-Label Belimumab | Part C: Safety Follow-up Phase |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/40 | 9/53 | 26/75 | 3/38 |
| Upper respiratory tract infectionInfections and infestations | 8/40 | 6/53 | 21/75 | 0/38 |
| PharyngitisInfections and infestations | 3/40 | 3/53 | 19/75 | 0/38 |
| HeadacheNervous system disorders | 10/40 | 7/53 | 16/75 | 0/38 |
| GastroenteritisInfections and infestations | 3/40 | 2/53 | 17/75 | 0/38 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/40 | 3/53 | 16/75 | 0/38 |
| Urinary tract infectionInfections and infestations | 4/40 | 1/53 | 13/75 | 0/38 |
| AnaemiaBlood and lymphatic system disorders | 3/40 | 0/53 | 12/75 | 0/38 |
| NeutropeniaBlood and lymphatic system disorders | 1/40 | 3/53 | 12/75 | 0/38 |
| DiarrhoeaGastrointestinal disorders | 3/40 | 7/53 | 12/75 | 0/38 |
| Age, Continuous(Years) | Part A: Placebo | Part A: Belimumab 10 mg/kg | Total |
|---|---|---|---|
| Mean | 14.8 ± 2.17 | 13.5 ± 2.59 | 14.0 ± 2.49 |
| Sex: Female, Male(Participants) | Part A: Placebo | Part A: Belimumab 10 mg/kg | Total |
|---|---|---|---|
| Female | 39 | 49 | 88 |
| Male | 1 | 4 | 5 |
| Race/Ethnicity, Customized(Participants) | Part A: Placebo | Part A: Belimumab 10 mg/kg | Total |
|---|---|---|---|
| Race customized — White - White/Caucasian/European Heritage | 21 | 27 | 48 |
| Race customized — Asian | 6 | 8 | 14 |
| Race customized — African American/African Heritage | 2 | 3 | 5 |
| Race customized — American Indian or Alaskan Native | 11 | 15 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://d3l8i7lo48obsd.cloudfront.net/gsk-patient-level-data-sharing-july2025-1-Bgwa1UthxvluYbWYTThw.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · d3l8i7lo48obsd.cloudfront.net
Ran from Sep 2012 to primary completion in Jan 2018, 64 months.
Results were first posted in Aug 2018, 6 months after primary completion.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 64 months is above that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →